Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E.
Target Price
The average target price of ADOC.PA is 14 and suggests 115% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell